Febrile Neutropenia
158 drugs160,759 FAERS reportsMedDRA PT
GET
/api/v1/reaction/febrile-neutropeniaReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
DefinitionNLM MeSH D064147
Fever accompanied by a significant reduction in the number of NEUTROPHILS.
Source: U.S. National Library of Medicine — MeSH (Febrile Neutropenia)
Drugs reporting Febrile Neutropenia (158)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Dyclonine4037%
- 2Cellulase225%
- 3Pancreatin225%
- 4Thioguanine48223%
- 5Fosamprenavir2519%
- 6Gemtuzumab Ozogamicin69419%
- 7Daunorubicin62317%
- 8Mesna1,27315%
- 9Dexrazoxane13715%
- 10Vincristine4,31515%
- 11Glasdegib6815%
- 12Idarubicin14413%
- 13Pegaspargase1,57313%
- 14Cytarabine7,90613%
- 15Ifosfamide2,63913%
- 16Mitoxantrone75812%
- 17Clofarabine27012%
- 18Vorinostat23911%
- 19Azurite111%
- 20Cornsilk111%
- 21Pentamidine13411%
- 22Mercaptopurine1,87711%
- 23Filgrastim4,50811%
- 24Etoposide7,58410%
- 25Azacitidine2,89410%
- 26Palifermin3910%
- 27Doxorubicin9,2769.9%
- 28Decitabine4889.9%
- 29Plerixafor1429.8%
- 30Eribulin3298.9%
- 31Inotuzumab Ozogamicin2548.9%
- 32Topotecan5998.8%
- 33Dactinomycin1918.8%
- 34Vinblastine1678.8%
- 35Dacarbazine6248.6%
- 36Thiotepa7968.6%
- 37Carmustine3778.3%
- 38Asparaginase258.3%
- 39Cyclophosphamide14,2188.3%
- 40Dimenhydrinate8468.1%
- 41Bleomycin8208.1%
- 42Rasburicase1857.9%
- 43Nelarabine757.9%
- 44Rimantadine27.7%
- 45Brentuximab Vedotin7257.3%
- 46Granisetron8687.3%
- 47Fludarabine2,7807.3%
- 48Eflapegrastim27.1%
- 49Cabazitaxel2447.1%
- 50Trabectedin1597.0%
- 51Obecabtagene Autoleucel26.7%
- 52Posaconazole1,0396.6%
- 53Micafungin5396.5%
- 54Obinutuzumab1,0316.5%
- 55Lifileucel156.3%
- 56Dexchlorpheniramine626.2%
- 57Gilteritinib2356.2%
- 58Ibritumomab Tiuxetan946.2%
- 59Palonosetron3796.1%
- 60Fosaprepitant8056.0%
- 61Epirubicin3645.9%
- 62Cisplatin4,4985.9%
- 63Pralatrexate385.9%
- 64Aprepitant1,0615.9%
- 65Quizartinib315.6%
- 66Prochlorperazine2,0305.5%
- 67Cefepime8505.4%
- 68Vinorelbine3655.4%
- 69Busulfan9715.4%
- 70Polatuzumab Vedotin4865.3%
- 71Melphalan1,3065.3%
- 72Carboplatin6,4355.2%
- 73Calaspargase Pegol345.1%
- 74Venetoclax3,0335.1%
- 75Bendamustine1,3104.9%
- 76Irinotecan5914.8%
- 77Glofitamab984.8%
- 78Cedazuridine364.7%
- 79Ixabepilone494.7%
- 80Docetaxel3,0314.6%
- 81Amifostine364.5%
- 82Pentostatin464.4%
- 83Sacituzumab1864.4%
- 84Lurbinectedin454.3%
- 85Netupitant474.3%
- 86Ramucirumab2604.3%
- 87Chlorambucil1624.2%
- 88Aldesleukin504.1%
- 89Isavuconazonium1414.1%
- 90Thymol144.0%
- 91Ondansetron4,7604.0%
- 92Talazoparib684.0%
- 93Uranium414.0%
- 94Temozolomide8214.0%
- 95Fluconazole2,6893.9%
- 96Naxitamab93.8%
- 97Pegfilgrastim3,8033.8%
- 98Paclitaxel3,6323.8%
- 99Diflorasone73.8%
- 100Fluorouracil2,8373.8%
- 101Treosulfan943.7%
- 102Tisagenlecleucel1663.7%
- 103Caspofungin1663.6%
- 104Ceftazidime2723.5%
- 105Meropenem1,1033.5%
- 106Gemcitabine1,8023.5%
- 107Amphotericin6953.4%
- 108Amphotericin B6953.4%
- 109Piperacillin1,1133.4%
- 110Potassium Phosphate1073.4%
- 111Leucovorin6293.4%
- 112Tazobactam1,1143.3%
- 113Pemetrexed1,2083.3%
- 114Itraconazole3703.2%
- 115Lisocabtagene Maraleucel253.1%
- 116Axicabtagene Ciloleucel2933.1%
- 117Valacyclovir2,1143.1%
- 118Interleukin-10113.1%
- 119Interleukin-11113.1%
- 120Interleukin-3113.1%
- 121Interleukin-5113.1%
- 122Dexamethasone9,1823.0%
- 123Tranexamic Acid2603.0%
- 124Metoclopramide2,2843.0%
- 125Voriconazole8953.0%
- 126Naldemedine473.0%
- 127Anidulafungin452.9%
- 128Mitotane502.9%
- 129Sodium Phosphate5022.8%
- 130Romidepsin462.8%
- 131Temsirolimus1252.8%
- 132Levoleucovorin982.7%
- 133Cefixime792.7%
- 134Famciclovir702.6%
- 135Sargramostim432.6%
- 136Isatuximab1352.6%
- 137Atezolizumab9292.5%
- 138Oxaliplatin1,7822.5%
- 139Acyclovir2,7882.5%
- 140Pertuzumab7532.5%
- 141Atovaquone2372.4%
- 142Letermovir702.3%
- 143Ivosidenib442.3%
- 144Cladribine2092.3%
- 145Mitomycin722.2%
- 146Mosunetuzumab182.2%
- 147Tremelimumab852.2%
- 148Lomustine542.2%
- 149Vancomycin1,3672.1%
- 150Idelalisib1492.1%
- 151Trastuzumab1,6821.9%
- 152Daratumumab7811.9%
- 153Tisotumab161.9%
- 154Entecavir1921.7%
- 155Elotuzumab851.7%
- 156Durvalumab2991.6%
- 157Blinatumomab304—
- 158Brexucabtagene Autoleucel80—
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
- Neutropenia127 shared · 0.50
- Thrombocytopenia109 shared · 0.39
- Pancytopenia63 shared · 0.33
- Sepsis91 shared · 0.33
- Disease Progression86 shared · 0.28
- Platelet Count Decreased66 shared · 0.27
- Anaemia121 shared · 0.24
- Myelosuppression36 shared · 0.21
- White Blood Cell Count Decreased42 shared · 0.21
- Malignant Neoplasm Progression52 shared · 0.20
Literature
Recent PubMed references pinned to Febrile Neutropenia as a MeSH major topic. About the reaction term itself — not about any specific drug.
- [Chinese guidelines for the clinical application of antibacterial drugs for febrile neutropenia (2026)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026 · Chinese Society of Hematology, Chinese Medical Association, Chinese Medical Doctor Association, Hematology BranchPMID 42161653DOI 10.3760/cma.j.cn121090-20260120-00041
- Mapping supportive-care evidence for febrile neutropenia prevention in breast cancer chemotherapy: a bibliometric analysis of long-acting G-CSF prophylaxis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · Li S, Shang Y, Yuan X, et al.PMID 42149261DOI 10.1007/s00520-026-10780-1
- Plasma Mid-Regional Pro-adrenomedullin as a Prognostic Biomarker in Hematopoietic Stem Cell Transplant Recipients with Febrile Neutropenia.Biological & pharmaceutical bulletin · 2026 · Iwao M, Tanaka R, Shiraiwa K, et al.PMID 42128870DOI 10.1248/bpb.b25-00750
- Piperacillin-tazobactam versus cefepime monotherapy in pediatric patients with febrile neutropenia: a systematic review and meta-analysis.European journal of pediatrics · 2026 · Fernandes BLG, Joseph A, Andriazzi VH, et al.PMID 42096109DOI 10.1007/s00431-026-07003-4
- Sacituzumab-induced severe or febrile neutropenia and G-CSF utilization and cost for advanced HER2-negative breast cancer: a single-center retrospective analysis.Breast cancer research and treatment · 2026 · Tam G, Waddell D, Freeman JQ, et al.PMID 41991763DOI 10.1007/s10549-026-07971-z
- Early discontinuation of empirical antibiotics versus extended treatment in children with cancer and high-risk febrile neutropenia in Denmark: an open-label, randomised controlled trial.The Lancet. Child & adolescent health · 2026 · Vissing NH, Skajaa T, Grosen D, et al.PMID 41990768DOI 10.1016/S2352-4642(26)00039-8
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.